Mr Francis Chinegwundoh : Consultant urologist, Harley Street, London

Academic Qualifications

Awards

Professional memberships

• British Association of Urological Surgeons
• European Association of Urology
• British Medical Association
• The Royal Society of Medicine
• UK Register of Expert Witnesses
• Independent Doctors Forum
• London Consultants Association

Research interests

Prostate

• Participant in multi-centre study of transurethral vaporisation of prostate (TVP) versus transurethral resection of prostate (TURP) 1998-2000. Funded by NHS health technology assessment
• TUNA. Contributing data into the European Association of Urology Central Registry 2004 - ongoing
• Prostate Cancer in Ethnic Subgroups (PROCESS) - incidence, presentation and access to health care. He is a co-recipient of a grant from the Department of Health. It is previewed on BBC online. The study commenced in 2003. Study centres in London and Bristol
• Ethnicity and prostate cancer in East London. He has published the first UK data demonstrating an increased incidence of prostate cancer in black men in a UK population.
• Prognostic factors in prostate cancer patients treated by watchful waiting. A joint study between Memorial Sloan Kettering Institute in New York and various UK institutions. 1999 - ongoing. This will lead to better identification of those men who can be safely kept under "watchful waiting" rather than undergo radical treatment for prostate cancer
• Intermittent hormone therapy with immediate versus deferred radiation localised prostate cancer. Lead clinician and originator for this Barts and The London study. Six years into a ten year study.
• European study [SEUG9001] into intermittent androgen suppression in prostate cancer
• Phase 2 study of safety and tolerability of FE200486 (LHRH antagonist) in prostate cancer. Completed 2003
• Dutasteride versus placebo for 4 years to reduce risk of biopsy detected prostate cancer. He is actively recruting into this study. It is for men with suspected prostate cancer but with a negatiave biopsy. Research suggest that 30% may subsequently be diagnosed with prostate cancer. The study is to find out if the drug dutasteride can reduce this risk. It is a multi-centre International study
• Mitoxantrone and prednisolone and YM598 or placebo in hormone refractory prostate cancer. 2003. Recruitment complete
• Lamins, capsaises and granzyme in prostate cancer. Supported by Cancer Research Fund Barts and The London. Work completed 2004 by my research registrar for MD thesis. Joint supervision with histopathology
• P1NP versus bone scan in the staging of prostate cancer. 2002-04. Can a simple, cheap blood test replace bone scanning?
  Gene therapy for prostate cancer, 2005 ongoing. A collaboration with Institute of Cancer Research, Charterhouse Square, London

 Erectile dysfunction

• 2mg verus 3mg Uprima in erectile dysfunction. 2003. completed.
• Tadalafil versus sildenafil in the oral treatment of erectile dysfunction. 2003. Recruitment complete. A head to head study of the leading oral treatments 

 Female urology

• Duloxetine versus placebo in the treatment of predominant stress urinary incontinence. 2004. He is actively recruiting into this study. This is the first drug for stress incontinence. Studies over the years are promising. Multi-centre international study. 

 Imaging

• Virtual cystoscopy. This study is completed. It investigated using CT and 3-D reconstruction to image the bladder. Work has been presented at a National meeting and has been published. 

 Bladder cancer

• Liarazol in superficial bladder cancer. 1998-2000. Completed.

Contact details